www.fdanews.com/articles/138360-array-biopharma-licenses-cancer-drug-arry-543-to-aslan-pharmaceuticals

Array BioPharma Licenses Cancer Drug ARRY-543 to ASLAN Pharmaceuticals

July 13, 2011

ASLAN Pharmaceuticals and Array BioPharma announced a license agreement to develop Array’s HER2/EGFR inhibitor, ARRY-543, currently entering Phase II development for solid tumors.
MarketWatch